We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prevalence of KIT expression in human tumors.
- Authors
Went, Philip Th; Dirnhofer, Stephan; Bundi, Marcel; Mirlacher, Martina; Schraml, Peter; Mangialaio, Sara; Dimitrijevic, Sasa; Kononen, Juha; Lugli, Alessandro; Simon, Ronald; Sauter, Guido
- Abstract
KIT is a target for imatinib mesylate (Gleevec; Novartis Pharma, Basel, Switzerland). Gastrointestinal stromal tumors (GISTs) express KIT and respond favorably to imatinib therapy. To determine other tumors in which such a molecular targeted therapy might be indicated, we investigated KIT expression in different human tumor types. Because recent studies in GISTs suggest that KIT-activating mutations predict response to imatinib therapy, we also sequenced a subset of positive tumors.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Vol 22, Issue 22, p4514
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2004.10.125